Abstract
Chemotherapy has been shown to prolong survival and to be cost effective in the palliative treatment of non-small-cell lung cancer. A meta-analysis of 11 randomised trials has found a small benefit from combination chemotherapy in advanced NSCLC, increasing one-year survival rates from 5% to 15%. New combination regimens, especially carboplatin-paclitaxel, show higher response rates in selected patients, and promise improved survival rates, but this has yet to be confirmed in randomised trials.
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / secondary*
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Docetaxel
-
Gemcitabine
-
Humans
-
Lung Neoplasms / pathology*
-
Paclitaxel / analogs & derivatives
-
Paclitaxel / therapeutic use
-
Palliative Care
-
Taxoids*
-
Topoisomerase I Inhibitors
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Topoisomerase I Inhibitors
-
Deoxycytidine
-
Docetaxel
-
Paclitaxel
-
Gemcitabine